Latest Ratios: P/E Ratio 3.4x · EV/EBITDA N/A · ROE 3.7%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $22M | — | — | — | — | $16M | $710169 | $2M | — |
| Enterprise Value | $22M | — | — | — | — | $16M | $1M | $1M | — |
| P/E Ratio → | 3.43 | — | — | — | — | — | 0.28 | 1.25 | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.13 | — | — | — | — | 0.30 | 0.01 | 0.01 | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | 0.13 | 0.31 | — |
| EV / EBIT | — | — | — | — | — | — | 0.13 | 0.31 | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 69.9% | — | — | — | — | — | — |
| Operating Margin | — | — | -18.4% | — | — | — | — | — | — |
| Net Profit Margin | — | — | -6.7% | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | 3.7% | 3.7% | -0.1% | — | — | -2.0% | 1.9% | 1.4% | -1.7% |
| ROA | 3.6% | 3.6% | -0.1% | -221.1% | -16.2% | -3.3% | 1.8% | 1.3% | -0.1% |
| ROIC | -0.4% | -0.4% | -0.2% | -949.2% | — | -1.6% | -0.6% | -0.5% | — |
| ROCE | -0.5% | -0.5% | -0.2% | — | — | -3.8% | -0.8% | -0.7% | -1.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | — | — | 0.09 | 0.01 | 0.00 | 23.19 |
| Debt / EBITDA | — | — | — | — | — | — | 0.05 | 0.20 | 10.07 |
| Net Debt / Equity | — | 0.00 | -0.00 | — | — | -0.00 | 0.00 | -0.00 | 16.85 |
| Net Debt / EBITDA | — | — | — | — | — | — | 0.04 | -0.10 | 7.32 |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -0.14 | — | — | — | -0.25 | -0.28 | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.07 | 0.07 | 3.09 | 0.00 | 0.12 | 0.19 | 0.16 | 1.38 | 0.27 |
| Quick Ratio | 0.07 | 0.07 | 3.09 | 0.00 | 0.12 | 0.19 | 0.16 | 1.38 | 0.27 |
| Cash Ratio | 0.05 | 0.05 | 2.08 | 0.00 | 0.00 | 0.18 | 0.05 | 1.31 | 0.27 |
| Asset Turnover | — | — | 0.01 | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 29.1% | — | — | — | — | — | 360.0% | 80.0% | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | — | — | — | — | 81.8% | 100.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | — | — | — | — | 81.8% | 100.0% | 0.0% | — |
| Shares Outstanding | — | $17M | $4M | $4M | $4M | $7M | $7M | $6M | $6M |
Imminent Liquidation and Insolvency
According to recent financial data, TDACW trades at a P/E of 3.43 and a P/B of 0.13, metrics that appear largely disconnected from fundamental performance given the entity's lack of revenue and the speculative nature of its search-phase business model within the biotech sector.
The low P/B ratio suggests that the market is pricing the entity at a significant discount to its book value, likely reflecting deep skepticism regarding the sponsor's ability to execute a merger. Investors should monitor whether this valuation gap represents a genuine mispricing of the warrant's option value or a rational assessment of the high probability of liquidation.
Based on reported figures, TDACW's ROIC has fluctuated near zero or negative levels, such as the -0.1% observed in 2026Q1, which is consistent with an entity that has yet to deploy capital into an operating business or generate any return on its invested assets.
The lack of meaningful ROIC trends indicates that the company is currently a capital-consuming vehicle rather than a compounding one. Any future improvement in these metrics will be entirely contingent upon the successful identification and acquisition of a target, rendering historical return data largely irrelevant for predictive modeling.
As reported in financial statements, the current ratio has deteriorated to 0.09 as of 2026Q1, signaling that the entity's cash reserves are insufficient to cover its short-term administrative obligations without reliance on external sponsor support or further capital injections to maintain its public listing status.
This liquidity profile suggests a highly vulnerable position where the entity lacks the necessary financial buffer to navigate regulatory or search-related delays. The rapid decline in the current ratio over the observed periods warrants further investigation into the sponsor's willingness to continue funding the entity's ongoing maintenance costs.
The P/E ratio is the most commonly misapplied metric for TDACW, as it obscures the reality that reported net income is driven by non-cash accounting adjustments for warrant liabilities rather than operational profitability, which remains non-existent for this pre-revenue shell company.
Investors should instead focus on the 'Time to Liquidation' and the 'Sponsor Support Level' as primary indicators of value. Relying on earnings-based multiples for a SPAC in the search phase may lead to a fundamental misunderstanding of the entity's risk profile and its actual economic viability.
Includes 30+ ratios · 8 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TDACW stock.
Translational Development Acquisition Corp.'s current P/E ratio is 3.4x. The historical average is 0.8x. This places it at the 100th percentile of its historical range.
Translational Development Acquisition Corp.'s return on equity (ROE) is 3.7%. The historical average is 0.5%.
Based on historical data, Translational Development Acquisition Corp. is trading at a P/E of 3.4x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.